Vyvanse patent expiration generic availability?

Vyvanse (lisdexamfetamine dimesylate) is a brand-name ADHD medication. Patent protection and the timing of generic availability depend on the country.

- United States: The core patent protection for Vyvanse has varied with multiple patents and exclusivities. In recent years, the key patents have expired or were expiring around 2023–2024, which opened the door for generic lisdexamfetamine products. Since then, several manufacturers have launched or announced generics, but exact availability can depend on settlements, pediatric exclusivity, and which specific product formulations are covered.
- Other regions: Patent protection and generic entry dates differ by country. Some places may have generics available earlier, others later, or only legal-pacified substitutes.

Important notes:
- Even after patent expiration, there can be regulatory exclusivities (e.g., pediatric exclusivity) or other patent protections that delay generic entry.
- When a generic is available, it is usually listed as therapeutically equivalent (AB rating in the U.S. Orange Book), making substitution with a generic pharmacist option common in many places.

If you’d like, I can help you get the current, country-specific status:
- Tell me your country/region (e.g., United States, EU country, Canada, etc.).
- I can guide you to the exact patent/exclusivity expiration dates and which generics are approved or available there (via the FDA Orange Book or the relevant regulatory database).